FrancoAntonio BFelizartaMD
Infectious Disease • Bakersfield, CAHIV/AIDS Medicine
solo private practice
Dr. Felizarta is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
3535 San Dimas Street
Suite 24
Bakersfield, CA 93311Phone+1 661-324-3128Fax+1 661-324-1129- Is this information wrong?
Education & Training
- SUNY Downstate Health Sciences UniversityFellowship, Infectious Disease, 1995 - 1997
- SUNY Health Science Center at BrooklynResidency, Internal Medicine, 1992 - 1995
- University of the Philippines College of MedicineClass of 1991
Certifications & Licensure
- CA State Medical License 1997 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Infectious Disease
Clinical Trials
- DART II - A Phase IV Study of 3 Antiretroviral Medicines in Combination, in HIV Patients Who Have Not Been Previously Treated With Antiretroviral Therapy Start of enrollment: 2002 Mar 01
Completed
Phase 4
- QUALITE Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection Start of enrollment: 2004 Jun 01
Completed
Phase 4
- A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults Start of enrollment: 2005 Aug 01
Terminated
Phase 2
- Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects Start of enrollment: 2005 Nov 02
Completed
Phase 2
- BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1. Start of enrollment: 2006 Mar 01
Completed
Phase 4
- Safety and Effectiveness of 3 Doses of Crofelemer Compared to Placebo in the Treatment of HIV Associated Diarrhea Start of enrollment: 2007 Oct 01
Completed
Phase 3
- Utilization of HIV Drug Resistance Testing in Treatment Experienced Patients (UTILIZE Study) Start of enrollment: 2007 Mar 01
Completed
- Prospective Observational Epidemiologic Study of Maraviroc's Safety Start of enrollment: 2008 Mar 31
Completed
- Phase IIa Dose-ranging Study of GSK1349572 in HIV-1 Infected Adults Start of enrollment: 2008 Jun 01
Completed
Phase 2
- A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive Subjects Start of enrollment: 2009 Jul 30
Completed
Phase 2
- Observational Prospective Registry of the Efficacy, Safety, and Adherence to Infergen® in Patients Infected With Hep C Start of enrollment: 2009 Aug 01
Withdrawn
- Boosted Lexiva With Lovaza Adjunctive Therapy in Hypertriglyceridemic, HIV-Infected Subjects Start of enrollment: 2009 Sep 01
Completed
Phase 4
- Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine Start of enrollment: 2010 Mar 22
Completed
Phase 1
- A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE) Start of enrollment: 2010 Apr 01
Completed
Phase 4
- Dose-finding Study of GSK2248761 in Antiretroviral Therapy-experienced Subjects With NNRTI-resistant HIV Infection Start of enrollment: 2010 Oct 05
Terminated
Phase 2
- Efficacy and Safety of GSK Biologicals HIV Vaccine in Antiretroviral Therapy (ART)-naïve HIV-1 Infected Persons Start of enrollment: 2010 Nov 08
Completed
Phase 2
- A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults Start of enrollment: 2010 Oct 26
Completed
Phase 3
- A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial) Start of enrollment: 2011 Feb 01
Completed
Phase 3
- An Efficacy, Safety and Tolerability Study of TMC435 in Genotype 1 Hepatitis C-infected Patients Who Relapsed After Previous Therapy Start of enrollment: 2011 Feb 01
Completed
Phase 3
- An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Patients Start of enrollment: 2011 Feb 01
Completed
Phase 3
- A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study Start of enrollment: 2011 Dec 01
Completed
Phase 3
- A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B Start of enrollment: 2011 May 18
Completed
Phase 4
- 3-year Follow-up Study in Patients Previously Treated With TMC435-Containing Regimen for the Treatment of Hepatitis C Virus Infection Start of enrollment: 2011 Jul 04
Completed
Phase 3
- Safety and Tolerability of Crofelemer for HIV-Associated Diarrhea Start of enrollment: 2011 Jun 07
Completed
Phase 3
- Gilead Sustained Virologic Response (SVR) Registry Start of enrollment: 2012 Apr 13
Completed
- A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response Start of enrollment: 2011 Dec 19
Completed
- ABT-450 With Ritonavir and ABT-267 and/or ABT-333 With and Without Ribavirin in Genotype 1 Hepatitis C Virus Infected Patients Start of enrollment: 2011 Oct 01
Completed
Phase 2
- A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients Start of enrollment: 2012 Jan 01
Completed
Phase 2
- A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV) Start of enrollment: 2011 Dec 01
Terminated
Phase 3
- Phase 3 Study of Sofosbuvir and Ribavirin Start of enrollment: 2011 Dec 01
Completed
Phase 3
- Alisporivir With PEG and RBV in Protease Inhibitor (PI) Treatment Failure Patients With Chronic Hepatitis C Start of enrollment: 2012 Mar 01
Terminated
Phase 3
- Study to Assess the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ABT-267 in HCV Infected Subjects Start of enrollment: 2012 Feb 01
Completed
Phase 2
- Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to Raltegravir and/or Elivitegravir Start of enrollment: 2012 Apr 18
Completed
Phase 3
- Long-term Observational Study in HIV Subjects Exposed to EGRIFTA® Start of enrollment: 2013 Feb 01
Terminated
- Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies Start of enrollment: 2012 Jun 01
Completed
Phase 3
- Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine Start of enrollment: 2012 Aug 06
Completed
Phase 2
- A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection Start of enrollment: 2012 Aug 01
Completed
Phase 2
- A Follow up Study Designed to Obtain Long Term Data on Participants Who Either Achieved a Sustained Virologic Response or Did Not Achieve a Sustained Virologic Response in an AbbVie Sponsored Hepatitis C Study Start of enrollment: 2013 Jun 01
Completed
Phase 3
- Safety, Tolerability, and Efficacy of 12-weeks of Sovaprevir, ACH-3102, and Ribavirin in Treatment-naive GT-1 HCV Participants Start of enrollment: 2013 Apr 01
Completed
Phase 2
- Dose-ranging Study of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Prevention of Complications of Early Decompensated Liver Cirrhosis Start of enrollment: 2013 Jun 01
Completed
Phase 2
- A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA) Start of enrollment: 2013 Aug 22
Completed
Phase 3
- An Open-label, Single Arm, Phase 2 Study to Evaluate ABT-450/r/ABT-267 and ABT-333 With Ribavirin (RBV) in Adults With Genotype 1 HCV Infection Taking Methadone or Buprenorphine Start of enrollment: 2013 Apr 01
Completed
Phase 2
- Collection of Plasma and Serum Samples From Individuals Initiating Sofosbuvir for Chronic Hepatitis C for Testing Start of enrollment: 2014 Feb 01
Completed
- Alisporivir With RBV in Chronic Hepatitis C Genotype 2 and 3 Participants for Whom Interferon is Not an Option Start of enrollment: 2014 Mar 01
Completed
Phase 2
- A Study to Examine Patient Characteristics, Health Care Management and Health Outcomes of Hepatitis C Virus (HCV) Patients Treated With Simeprevir Start of enrollment: 2014 Feb 01
Completed
- Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis Start of enrollment: 2014 Apr 01
Completed
Phase 3
- Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Chronic Hepatitis C Virus Infection Without Cirrhosis Start of enrollment: 2014 Apr 01
Completed
Phase 3
- A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection Start of enrollment: 2014 Jun 12
Completed
Phase 3
- One Year Study of Rifaximin Delayed Release (DR) Tablets in Crohn's Disease Start of enrollment: 2014 Aug 21
Terminated
Phase 3
- A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-administration of ABT-493 and ABT-530 With and Without Ribavirin in Subjects With HCV Genotype 1, 4, 5, and 6 Infection Start of enrollment: 2014 Aug 01
Completed
Phase 2
- A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection Start of enrollment: 2014 Sep 19
Completed
Phase 2, Phase 3
- Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1) (MK-1439-018) Start of enrollment: 2014 Dec 01
Completed
Phase 3
- Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Simeprevir, Daclatasvir and Sofosbuvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection Start of enrollment: 2015 Jan 01
Completed
Phase 2
- Comparison of Doravirine, Tenofovir, Lamivudine (MK-1439A) and ATRIPLA™ in Treatment-Naive Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439A-021) Start of enrollment: 2015 Jun 05
Completed
Phase 3
- A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530 Start of enrollment: 2015 Jun 22
Completed
Phase 2, Phase 3
- A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-493 and ABT-530 With and Without Ribavirin in Adults With HCV Who Failed a Prior DAA Containing Therapy Start of enrollment: 2015 Apr 01
Completed
Phase 2, Phase 3
- AURORA: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH) Start of enrollment: 2017 Apr 05
Terminated
Phase 3
- Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Participants With Nonalcoholic Steatohepatitis Start of enrollment: 2017 Feb 14
Terminated
Phase 2
- A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults With Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Compensated Cirrhosis Start of enrollment: 2017 Apr 28
Completed
Phase 3
- A Study to Evaluate the Efficacy and Safety of (D/C/F/TAF) Once Daily Fixed Dose Combination (FDC) Regimen in Newly Diagnosed, Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Receiving Care in a Test and Treat Model of Care Start of enrollment: 2017 Jul 31
Completed
Phase 3
- Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD) Start of enrollment: 2017 Aug 22
Completed
Phase 2
- An Efficacy, Safety, and Pharmacokinetics Study of JNJ-56136379 in Participants With Chronic Hepatitis B Virus Infection Start of enrollment: 2018 Feb 13
Completed
Phase 2
- A Study To Assess Pharmacodynamics, Safety And Tolerability Of PF-05221304 And PF-06865571 Co-Administered For 6 Weeks In Adults With Non-Alcoholic Fatty Liver Disease. Start of enrollment: 2019 Jan 04
Completed
Phase 2
- ACTIV-2: A Study for Outpatients With COVID-19 Start of enrollment: 2020 Aug 19
Completed
Phase 2, Phase 3
- Study in Participants With Early Stage Coronavirus Disease 2019 (COVID-19) to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation Start of enrollment: 2020 Sep 14
Completed
Phase 1, Phase 2
- Join now to see all
Publications & Presentations
PubMed
- Boceprevir for untreated chronic HCV genotype 1 infection.Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowic...> ;The New England journal of medicine.
- Racial differences in hepatitis C treatment eligibility.Melia MT, Muir AJ, McCone J, Shiffman ML, King JW, Herrine SK, Galler GW, Bloomer JR, Nunes FA, Brown KA, Mullen KD, Ravendhran N, Ghalib RH, Boparai N, Jiang R, Novie...> ;Hepatology (Baltimore, Md.).
- Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.Walmsley SL, Antela A, Clumeck N, Duiculescu D, Eberhard A, Gutiérrez F, Hocqueloux L, Maggiolo F, Sandkovsky U, Granier C, Pappa K, Wynne B, Min S, Nichols G, SINGLE ...> ;The New England journal of medicine.
- Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic h...Yuen MF, Asselah T, Jacobson IM, Brunetto MR, Janssen HLA, Takehara T, Hou JL, Kakuda TN, Lambrecht T, Beumont M, Kalmeijer R, Guinard-Azadian C, Mayer C, Jezorwski J,...> ;The lancet. Gastroenterology & hepatology. 2023-07-10
- 1 citationsFactors Associated with Health Care Providers' Preference for Forgoing an Oral Lead-In Phase When Initiating Long-Acting Injectable Cabotegravir and Rilpivirine in the...Tahilin Sanchez Karver, Miguel Pascual-Bernaldez, Alessandro Berni, Ahmed Hnoosh, Antonella Castagna, Peter Messiaen, Maria Jose Galindo Puerto, Mark Bloch, Eisuke Ada...> ;AIDS Patient Care and Stds. 2023 Jan 1
- 2 citationsDurability of sustained virological response to glecaprevir/pibrentasvir and resistance development: A long-term follow-up study.Fred Poordad, Franco Felizarta, Betty B Yao, J Scott Overcash, Tarek Hassanein, Kosh Agarwal, Edward Gane, David Shaw, Michael Waters, Preethi Krishnan, Andrew Topp, M...> ;Liver International. 2022 Jun 1
- 5 citationsPhase IIa Proof-of-Concept Evaluation of the Antiviral Efficacy, Safety, Tolerability, and Pharmacokinetics of the Next-Generation Maturation Inhibitor GSK3640254.Christoph D Spinner, Franco Felizarta, Giuliano Rizzardini, Patrick Philibert, Essack Mitha, Pere Domingo, Christoph J Stephan, Michelle DeGrosky, Veronica Bainbridge,...> ;Clinical Infectious Diseases. 2022 Sep 14
- 9 citationsLong‐term safety and efficacy results in hepatitis C virus genotype 1‒infected patients receiving ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in the TOPA...Fred Poordad, Rui Sarmento e Castro, Armen Asatryan, Humberto Aguilar, Patrice Cacoub, Douglas T. Dieterich, Rui Tato Marinho, Armando Carvalho, Asma Siddique, Yiran B...> ;Journal of Viral Hepatitis. 2020 May 1
- 19 citationsPharmacokinetics and antiviral activity of cabotegravir and rilpivirine in cerebrospinal fluid following long-acting injectable administration in HIV-infected adultsScott Letendre, Anthony Mills, Debbie Hagins, Susan Swindells, Franco Felizarta, Jerome deVente, Christopher J Bettacchi, Yu Lou, Susan L. Ford, Kenneth Sutton, Jafar ...> ;The Journal of Antimicrobial Chemotherapy. 2020 Mar 1
- 12 citationsA Phase IIa Study Evaluating Safety, Pharmacokinetics, and Antiviral Activity of GSK2838232, a Novel, Second-generation Maturation Inhibitor, in Participants With Huma...Edwin DeJesus, Sara Duckworth Harward, Roxanne C. Jewell, Mark Johnson, Etienne Dumont, Viviana Wilches, Fiona Halliday, Christine L. Talarico, Jerry Jeffrey, Jianjun ...> ;Clinical Infectious Diseases. 2020 Aug 22
- 95 citationsGlecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: The EXPEDITION-8 trial.Robert S. Brown, Maria Buti, Lino Rodrigues, Vladimir Chulanov, Wan-Long Chuang, Humberto Aguilar, Gabor Horvath, E. Zuckerman, Barbara Rosado Carrion, Federico Rodrig...> ;Journal of Hepatology. 2020 Mar 1
- Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority...Molina JM, Squires K, Sax PE, Cahn P, Lombaard J, DeJesus E, Lai MT, Rodgers A, Lupinacci L, Kumar S, Sklar P, Hanna GJ, Hwang C, Martin EA, DRIVE-FORWARD trial group> ;The lancet. HIV. 2019-11-15
- Week 48 Resistance Analyses of the Once-Daily, Single-Tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 f...Lathouwers E, Wong EY, Brown K, Baugh B, Ghys A, Jezorwski J, Mohsine EG, Van Landuyt E, Opsomer M, De Meyer S, AMBER and EMERALD Study Groups> ;AIDS research and human retroviruses. 2019-10-21
- Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disopr...Eron JJ, Orkin C, Cunningham D, Pulido F, Post FA, De Wit S, Lathouwers E, Hufkens V, Jezorwski J, Petrovic R, Brown K, Van Landuyt E, Opsomer M, EMERALD study group> ;Antiviral research. 2019-07-04
- 23 citationsSafety and efficacy of glecaprevir/pibrentasvir in patients with chronic hepatitis C genotypes 1-6 receiving opioid substitution therapy.Jason Grebely, Gregory J. Dore, Negar N. Alami, Brian Conway, John F. Dillon, Michael Gschwantler, Franco Felizarta, Christophe Hézode, Krzysztof Tomasiewicz, Linda M ...> ;The International Journal on Drug Policy. 2019 Apr 1
- 10 citationsEfficacy and safety of 6 or 8 weeks of simeprevir, daclatasvir, sofosbuvir for HCV genotype 1 infection.Mark S. Sulkowski, Jordan J. Feld, Eric Lawitz, Franco Felizarta, A. Corregidor, O. Khalid, R. Ghalib, William B. Smith, V. Van Eygen, Donghan Luo, Leen Vijgen, M. Gam...> ;Journal of Viral Hepatitis. 2018 Jun 1
- Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-in...Molina JM, Squires K, Sax PE, Cahn P, Lombaard J, DeJesus E, Lai MT, Xu X, Rodgers A, Lupinacci L, Kumar S, Sklar P, Nguyen BY, Hanna GJ, Hwang C, DRIVE-FORWARD Study ...> ;The lancet. HIV. 2018-03-25
- 109 citationsGlecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial.David L. Wyles, Fred Poordad, Stanley Wang, Laurent Alric, Franco Felizarta, Paul Y. Kwo, Benedict Maliakkal, Kosh Agarwal, Tarek Hassanein, Frank Weilert, Samuel S. L...> ;Hepatology. 2018 Feb 1
- 281 citationsGlecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , > ;The New England Journal of Medicine. 2018 Jan 24
- 105 citationsGlecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure.Fred Poordad, Stanislas Pol, Armen Asatryan, Maria Buti, David R. Shaw, Christophe Hézode, Franco Felizarta, Robert Reindollar, Stuart C. Gordon, Stephen Pianko, Micha...> ;Hepatology. 2018 Apr 1
- Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat,...Orkin C, Molina JM, Negredo E, Arribas JR, Gathe J, Eron JJ, Van Landuyt E, Lathouwers E, Hufkens V, Petrovic R, Vanveggel S, Opsomer M, EMERALD study group> ;The lancet. HIV. 2017-10-06
- 251 citationsGlecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open...Xavier Forns, Samuel S. Lee, Joaquin Mario Valdes, Sabela Lens, Reem Ghalib, Humberto Aguilar, Franco Felizarta, Tarek Hassanein, Holger Hinrichsen, Diego Rincón, Rosa...> ;The Lancet. Infectious Diseases. 2017 Oct 1
- 229 citationsGlecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1–6 without cirrhosisPaul Y. Kwo, Fred Poordad, Armen Asatryan, Stanley Wang, David L. Wyles, Tarek Hassanein, Franco Felizarta, Mark S. Sulkowski, E.J. Gane, Benedict Maliakkal, J Scott O...> ;Journal of Hepatology. 2017 Aug 1
- 141 citationsGlecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatmentFred Poordad, Franco Felizarta, Armen Asatryan, Mark S. Sulkowski, Robert Reindollar, Charles S. Landis, Stuart C. Gordon, Michael W. Fried, David E. Bernstein, C.-W. ...> ;Hepatology. 2017 Aug 1
- Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously un...Orrell C, Hagins DP, Belonosova E, Porteiro N, Walmsley S, Falcó V, Man CY, Aylott A, Buchanan AM, Wynne B, Vavro C, Aboud M, Smith KY, ARIA study team> ;The lancet. HIV. 2017-07-17
- Join now to see all
Press Mentions
- Fast Vaccine Rollout Sought to Fight DeltaJuly 21st, 2021
Professional Memberships
- Fellow
- Member
- Member
- Member
Other Languages
- Tagalog
Hospital Affiliations
- Bakersfield Heart HospitalBakersfield, California
- Bakersfield Memorial HospitalBakersfield, California
- Mercy Hospital DowntownBakersfield, California
- Adventist Health BakersfieldBakersfield, California
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
Similar Physicians & HCPs
Doximity / States / California / Bakersfield / Franco Felizarta, MD
Dr. Franco Felizarta, Dr. Franco Felizarta, MD, Dr. F Felizarta, Dr. Franco Antonio B Felizarta